COVID-19 represents an unprecedented health, social and economic challenge in Australia and around the world. Support Burnet’s COVID-19 emergency response today.
Geoff Drenkhahn is an executive with 20+ years of experience in the R+D sector with a record of identifying opportunities and developing strategies for expansion and growth, and building new business operations.
As Director, Strategic Funding & Partnerships he has responsibility for identifying income generation opportunities and the appropriate mechanisms for commercialisation of the Institute’s research portfolio. He brings a business perspective to the management of the R&D pipeline with a background in strategic planning, financial and contract management, business and organisational growth, and governance.
He currently represents Burnet on the board of four independent entities developing and commercialising Burnet technologies, Nanjing BioPoint, HepSeeVax, 360biolabs and Optima Consortium for Decision Science (OCDS).
Geoff is a member of the Institute’s Executive Committee, and the Budget and Investment Committee, and plays a lead role in the Institute’s strategic performance management i.e. monitoring and reporting of performance against the Institute’s strategic objectives.
He is the Institute’s previous Chief Operating Officer (2008-2016) and prior to that the Deputy Head of the Institute’s Centre of International Health. He joined the Institute in 1998 following a career with CSIRO and the Victoria State government.
Geoff has an MBA (Technology Management) from Deakin University and has completed executive education programs at Harvard Business School and Melbourne Business School. He is a Fellow of the Australian Institute of Management, a Graduate Member of the Australian Institute of Company Directors, and a Member of the Association for Strategic Planning.